A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous TAK-341 in Subjects With Multiple System Atrophy
This research study is looking at a new medicine called TAK-341 for people with Multiple System Atrophy (MSA). MSA is a rare and serious condition that affects movement, balance, and other body functions. The study aims to find out if TAK-341 is safe to use and how well it works. Participants will either receive TAK-341 or a 'dummy' treatment (placebo) given through a drip. Doctors will carefully check changes in their symptoms over 52 weeks, especially those related to movement and daily activities. This is an important step to see if TAK-341 could become a new treatment option for MSA.
En un coup d'œil
De quoi parle cette étude ?
This study is a research project focused on a condition called Multiple System Atrophy (MSA). MSA is a rare and progressive disease that affects the nervous system, leading to issues with movement, balance, and the control of automatic body functions like blood pressure and bladder control. Currently, there's no cure for MSA, and treatments mainly focus on managing symptoms.
Researchers are investigating a new medicine, TAK-341, which is a special type of antibody given through a drip. They believe this medicine might help by targeting specific proteins in the brain that are thought to be involved in MSA. The main goal is to see if TAK-341 can slow down the worsening of MSA symptoms over 52 weeks, compared to a placebo – which is a treatment that looks the same but contains no active medicine. This helps researchers understand the true effect of TAK-341.
This is a 'Phase 2' study, meaning it's an early but important stage of testing. It focuses on figuring out the right dose, checking for side effects, and getting an initial idea of how well the medicine works. The results from this study will help decide if TAK-341 should be tested in larger studies with more people in the future, hopefully bringing us closer to new treatments for MSA.
Points clés
- This is a study of a new medicine for Multiple System Atrophy (MSA).
- It aims to check the safety and potential benefits of TAK-341 over 52 weeks.
- Participants will receive either the new medicine or a dummy treatment (placebo).
- Symptoms will be closely monitored through regular clinic visits.
- The study is for adults aged 18 and over, with specific health criteria.
- Results will help decide if TAK-341 is a promising future treatment for MSA.
Qui peut être éligible ?
To join this study, people must be 18 years old or older. The study is open to both men and women. There will also be other specific health requirements that your doctor will need to check to make sure the study is a good fit for you and that it's safe for you to take part.
It's important that you discuss your full medical history with the study team. They will have a detailed list of what would allow you to participate and what would prevent you from doing so. This is to ensure your safety and the accuracy of the study results.
Cet étude pourrait-elle vous convenir ?
Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.
- Avez-vous 18 ans ou plus ?
- Do you have a confirmed diagnosis of Multiple System Atrophy?
- Are you able to attend regular clinic appointments for over a year?
- Are you willing to potentially receive a placebo instead of the active drug?
- Are you able to follow the study's instructions and procedures?
En quoi consiste la participation ?
If you decide to take part in this study, you will be given either the new medicine, TAK-341, or a placebo (a dummy medicine with no active ingredients). Both will be given through a drip into your arm (intravenously). You won't know which one you are receiving, nor will the study doctors, which helps make the results fair.
Over 52 weeks, you will have regular visits to the clinic. During these visits, doctors will perform various checks and tests. This includes looking at your movement, balance, and daily activities to see if your symptoms are changing. You might also have blood tests and other assessments to monitor your health, how the medicine is working, and to check for any side effects. After the 52 weeks of treatment, there will likely be follow-up appointments to continue monitoring your health.
Risques et avantages potentiels
Emplacements (7)
- —Non vérifiéDanemark
- —Non vérifiéItalie
- —Non vérifiéPortugal
- —Non vérifiéEspagne
- —Non vérifiéAllemagne
- —Non vérifiéFrance
- —Non vérifiéAutriche
Questions fréquentes
What is Multiple System Atrophy (MSA)?
MSA is a rare condition that affects the nervous system, impacting movement, balance, and automatic body functions.
What is TAK-341?
TAK-341 is a new experimental medicine, given through a drip, that researchers hope might help with MSA symptoms.
Que signifie 'placebo' ?
A placebo is a 'dummy' treatment that looks just like the real medicine but contains no active drug. It helps researchers compare the effects fairly.
Combien de temps durera l'étude ?
The main treatment period for the study is 52 weeks (about one year), with likely follow-up appointments after that.
Is this study suitable for everyone with MSA?
No, there are specific health requirements. Your doctor will need to check if you are eligible and if it's safe for you to take part.
Comment en savoir plus
Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.
Intéressé à participer ?
Discussion
Discussion communautaire
Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.